Su Youn Nam

USPTO Granted Patents = 6 (Patent Applications = 8)

CIPO Patents = 2 (Patent Applications = 3)

EPO Patents = 2 (Patent Applications = 8)

Average Co-Inventor Count = 6.6

ph-index = 1

Forward Citations = 4(Granted Patents)

Company Filing History:

Years Active: 2016-2024

Loading Chart...

6 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11857601 - Pharmaceutical composition for cancer treatment comprising fusion protein including IL-2 protein and CD80 protein and anticancer drug (2024-01-02),

2. 11639383 - Pharmaceutical composition for treatment of cancer, comprising an immune checkpoint inhibitor antibody and a fusion protein comprising an IL-2 mutant and a CD80 extracellular domain (2023-05-02),

3. 11142557 - Long-acting FGF21 fusion proteins and pharmaceutical composition comprising same (2021-10-12),

4. 11136364 - Dual function proteins comprising FGF21 mutant protein and pharmaceutical composition comprising same (2021-10-05),

5. 11046742 - Fusion protein comprising CCL3 variant and use thereof (2021-06-29),

6. 9493478 - Fused ring compound containing furan or salt thereof and pharmaceutical composition comprising same (2016-11-15),

Hello! I can provide you with an article about inventor Su Youn Nam. Here it is:

Title: Innovator Spotlight: Su Youn Nam - Revolutionizing Cancer Treatment

Introduction: Su Youn Nam, a brilliant inventor based in Seoul, South Korea, has made significant strides in the field of pharmaceuticals with a focus on cancer treatment. With a total of 6 patents to his name, Nam's innovative approach to enhancing immune activity for combatting cancer has garnered attention worldwide.

Latest Patents:

1. *Pharmaceutical Composition for Cancer Treatment Comprising Fusion Protein including IL-2 Protein and CD80 Protein and Anticancer Drug*: Nam's groundbreaking patent focuses on a pharmaceutical composition that includes a fusion protein containing an IL-2 protein and a CD80 protein, along with an anticancer agent. This composition not only activates immune cells such as natural killer cells but also controls the regulatory activity of T cells, leading to effective cancer inhibition.

2. *Pharmaceutical Composition for Treatment of Cancer, Comprising an Immune Checkpoint Inhibitor Antibody and a Fusion Protein Comprising an IL-2 Mutant and a CD80 Extracellular Domain*: In this patent, Nam introduces a pharmaceutical composition for preventing or treating cancer. The fusion protein, combined with an immune checkpoint inhibitor, demonstrates the ability to activate immune cells and inhibit cancer effectively.

Career Highlights: Throughout his career, Su Youn Nam has contributed his expertise to renowned companies such as Yuhan Corporation and GI Innovation, Inc. His dedication to developing novel pharmaceutical compositions has been instrumental in advancing cancer treatment strategies.

Collaborations: Nam has collaborated with esteemed professionals in the industry, including colleagues like Jong Gyun Kim and Jun Hwan Kim. Their collective efforts have led to impactful innovations in cancer research and treatment.

Conclusion: Su Youn Nam's inventive spirit and commitment to revolutionizing cancer treatment through his patented pharmaceutical compositions highlight his status as a leading innovator in the field. His relentless pursuit of novel solutions underscores the significant industrial potential of his creations, offering hope and progress in the fight against cancer.

Please let me know if you need any further information or assistance!

This text is generated by artificial intelligence and may not be accurate.